Program
coramitug
Also written as “Coramitug” and “PRX004”.
Its studies are mostly in Amyloidosis, led by 2 companies.
Furthest: phase 1, since Feb 26, 20262 company-led studies, 1 open or runningNext primary completion: May 30, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 11 open or running | phase 1since Feb 26, 2026 | Feb 26, 2026 | May 30, 2027phase 1 · NCT07448623 |
| Prothena Biosciences | 10 open or running | phase 1since Oct 23, 2017 | Oct 23, 2017 | none ahead |
- Named in Novo Nordisk’s own pipeline as
Coramitug in ATTR-CM
, phase 3, as of Nov 5, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 23, 2017First study: phase 1 study in AmyloidosisNew to Prothena BiosciencesProthena Biosciences · NCT03336580 · 21 enrolled · United States, Portugal, Spain and more
- Feb 26, 2026Novo Nordisk’s first study: phase 1 study in Transthyretin Amyloid CardiomyopathyNew to Novo NordiskNovo Nordisk · NCT07448623 · 14 planned · Netherlands
Ahead
- May 30, 2027Primary completion: phase 1 study in Transthyretin Amyloid CardiomyopathyNovo Nordisk · NCT07448623
TargetBeta
“Coramitug is a monoclonal antibody that potentially binds to the accumulations of the transthyretin protein and promotes its removal from the heart.”study summary, read by Claude · the study
Other programs on TTR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tafamidisrule | Pfizer | phase 4 | 29 |
| acoramidisrule | BridgeBio | phase 4 | 15 |
| coramitug | Novo Nordisk | phase 3 | 3 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07448623Transthyretin Amyloid Cardiomyopathy · Netherlands | 1 | Recruiting | Novo Nordisk | May 30, 2027 | 14 |
| NCT03336580Amyloidosis · United States, Portugal, Spain and more | 1 | Terminated | Prothena Biosciences | Jul 23, 2020 | 21 |
How it is read
Names in the registry
- “Coramitug”, 1 entry
- “PRX004”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.